• Injectable GelMA/QCS/Ca2+ Hydrogel: Hemostasis and Antibacte

  2026-05-15

  The referenced study introduces a blue light-activated injectable hydrogel adhesive composed of GelMA, quaternary ammonium chitosan (QCS), and Ca2+ ions, designed for rapid hemostasis and infection control in non-compressible wounds. Its dual-network structure yields superior mechanical, hemostatic, and antibacterial properties compared to single-function adhesives, offering promising implications for emergency trauma care and biomaterial evaluation.

• Olive Biophenols Attenuate Alzheimer’s Pathology In Vitro an

  2026-05-15

  This study demonstrates that olive-derived biophenols, particularly oleuropein, verbascoside, and rutin, significantly reduce amyloid beta aggregation and neurotoxicity in SH-SY5Y cells and APPswe/PS1dE9 transgenic mice. These findings highlight the therapeutic promise of natural biophenols in Alzheimer’s disease models and provide a foundation for future mechanistic and translational research.

• 17-AAG (Tanespimycin): Unlocking HSP90 Pathways in Translati

  2026-05-14

  This thought-leadership article explores the mechanistic underpinnings and translational strategies surrounding 17-AAG (Tanespimycin), a potent synthetic HSP90 inhibitor. Integrating recent advances in chaperone biology, apoptosis, and regulated DAMP release—including groundbreaking insights from the NINJ1 protein—we provide researchers with actionable guidance for maximizing the impact of HSP90 inhibition in cancer models. Distinct from standard product pages, this piece bridges mechanistic discovery, protocol optimization, and emerging clinical frontiers, empowering the next generation of translational oncology research.

• Aclacinomycin A: Applied DNA Damage & Apoptosis Research Gui

  2026-05-14

  Aclacinomycin A (Aclarubicin) is a precision tool for dissecting DNA damage responses and apoptosis with dual topoisomerase inhibition. This article details protocol enhancements, troubleshooting strategies, and workflow innovations based on recent nucleolar DNA damage research, establishing APExBIO’s Aclacinomycin A as a benchmark for high-fidelity cancer cell stress assays.

• ATRX-Deficient Glioma Sensitivity to RTK/PDGFR Inhibition

  2026-05-13

  This study demonstrates that high-grade glioma cells lacking ATRX exhibit heightened sensitivity to receptor tyrosine kinase (RTK) and PDGFR inhibitors. The findings highlight ATRX status as a potential biomarker for guiding targeted therapy strategies in glioma research.

• Phillygenin Mitigates Diabetic Nephropathy via Inflammatory

  2026-05-13

  This study identifies phillygenin as a promising intervention for diabetic nephropathy, demonstrating its ability to reduce inflammation and apoptosis through modulation of TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling. These findings provide molecular insights that could inform future therapeutic strategies in renal disease models.

• Sequencing Therapies in Waldenström Macroglobulinemia: Genom

  2026-05-12

  Sarosiek et al. provide a genomically informed framework for sequencing therapies in Waldenström Macroglobulinemia (WM), emphasizing the integration of MYD88 and CXCR4 mutation status into individualized treatment selection. This approach addresses the clinical heterogeneity of WM and offers practical guidance for optimizing patient outcomes in both frontline and relapsed settings.

• PCI-32765 (Ibrutinib): Optimizing BTK Inhibition in B-Cell R

  2026-05-12

  PCI-32765 (Ibrutinib) delivers reproducible, nanomolar BTK inhibition for precision B-cell signaling studies. This guide translates bench-proven workflows, protocol enhancements, and troubleshooting tactics for robust results in B-cell malignancy and autoimmune disease models.

• AG-126 (Tyrphostin AG-126): Precision Tools for ERK Pathway

  2026-05-11

  AG-126 (Tyrphostin AG-126) empowers researchers to dissect MAPK/ERK signaling in neuroinflammation and repetitive behavior models with selective, data-backed inhibition. Combining in vitro and in vivo versatility, this inhibitor stands out for its reproducibility and streamlined protocol optimization in studies of neuronal excitability and cytokine modulation.

• Jasplakinolide: Precision Actin Polymerization Inducer in Re

  2026-05-11

  Jasplakinolide is a highly potent actin polymerization inducer used in cytoskeletal studies. Its sub-nanomolar F-actin affinity and membrane permeability make it a gold-standard tool for dissecting actin dynamics and related cellular processes. This article details benchmarks, limitations, and best practices for laboratory use.

• MK-1775 (Wee1 Kinase Inhibitor): Optimizing In Vitro Assay D

  2026-05-10

  Explore the profound impact of MK-1775, a potent Wee1 kinase inhibitor, on assay design and interpretation in cancer research. This article uniquely bridges mechanistic insight with protocol optimization, informed by the latest reference methods.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-09

  This study introduces a patient-derived gastric cancer assembloid model that integrates tumor organoids with matched stromal cell subpopulations, capturing the complex cellular heterogeneity of primary tumors. The model provides a robust platform for studying tumor–stroma interactions, drug resistance, and personalized therapeutic strategies in gastric cancer research.

• HotStart Universal 2X Green qPCR Master Mix: Precision in Ge

  2026-05-09

  The HotStart™ Universal 2X Green qPCR Master Mix delivers exceptional specificity and reproducibility for real-time PCR gene expression analysis, empowering researchers to dissect stress-response pathways with confidence. This article bridges cutting-edge ER stress research with robust qPCR assay optimization, offering actionable protocol enhancements and troubleshooting strategies for advanced gene expression quantification.

• NT5DC2–ACSL3 Axis Suppresses Ferroptosis in Bladder Cancer C

  2026-05-08

  This study reveals that NT5DC2 impedes ferroptosis by stabilizing ACSL3, thereby promoting bladder cancer progression. The mechanistic insights into the NT5DC2–ACSL3 interaction highlight a potential therapeutic target and inform future autophagy and ferroptosis research.

• Deferiprone in Bench Research: Applied Protocols & Workflow

  2026-05-07

  Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) empowers researchers to precisely manipulate iron-dependent pathways, enabling apoptosis induction and cytoprotection assays in cancer and metabolic studies. This article translates the latest bench research—including iron stress metabolomics—into actionable protocols, troubleshooting strategies, and advanced applications using APExBIO’s Deferiprone.

16647 records 1/1110 page Next 12345 下5页 Last page